MENU CONTENTS

NEUROSTEM

Preventative Treatment of Alzheimer’s Disease (AD)NEUROSTEM®

뉴로스템

NEUROSTEM® is under-development for the treatment of Alzheimer’s disease, which is based on the Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell drug.

Currently, Phase 1/2a clinical trial of Ministry of Food & Drug Safety is ongoing and preparing for the clinical trial (FDA) in the U.S.

Product Name
NEUROSTEM®
Manufacturer
MEDIPOST
Indication
Preventive treatment of Alzheimer’s disease
Administration
Administration in cerebral ventricles
Before and After
NEUROSTEM®
(Animal
experiments)

손상된 뇌 Damaged brain

투여 10일 후 뇌 10 Days After

NEUROSTEM® Action Mechanism

Accumulation of β-amyloid, which causes Alzheimer-type dementia, induces learning and memorizing disorders by damaging nerve cells.

Once NEUROSTEM® is administrated to the patient’s brain with Alzheimer-type dementia, the protein secreted from umbilical cord blood-derived mesenchymal stem cells promotes degradation of β-amyloid by triggering secretion of β-amyloid degrading enzyme (usually secreted by microglia).

상단으로